NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INM
Post# of 33
(Total Views: 217)
Posted On: 08/23/2019 5:14:26 PM
NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Advances Clinical Development of INB03
INmune Bio (NASDAQ: INMB) co-founder and CEO Dr. RJ Tesi recently reported positive preliminary data from the company’s INB03 Phase I clinical trial in cancer patients during a presentation at Cambridge Healthtech Institute’s 7th Annual Immuno-Oncology Summit in Boston (http://nnw.fm/Wu2Ao). An article discussing the company reads, “‘The goal of the Phase I study is to determine, in order of priority, the safety of INB03 in cancer patients, the dose of INB03 to take into the Phase II trials in cancer, and evidence of a biologic effect of INB03,’ stated Tesi, who is also INmune Bio’s chief medical officer. ‘All of these goals have been met. Using data from this trial, we have begun planning a Phase II trial using INB03 as part of combination immunotherapy in patients with cancer.’ . . . The Phase I trial is an open-label, dose-escalation trial in patients with advanced solid tumors. Patients received INB03, a novel, second-generation soluble TNF (tumor necrosis factor) inhibitor that works by leveraging a dominant-negative technology. Positive preliminary data from the first two cohorts were released. That data will be followed by a final report later this year as the company advances the program into a Phase II study.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
INmune Bio (NASDAQ: INMB) co-founder and CEO Dr. RJ Tesi recently reported positive preliminary data from the company’s INB03 Phase I clinical trial in cancer patients during a presentation at Cambridge Healthtech Institute’s 7th Annual Immuno-Oncology Summit in Boston (http://nnw.fm/Wu2Ao). An article discussing the company reads, “‘The goal of the Phase I study is to determine, in order of priority, the safety of INB03 in cancer patients, the dose of INB03 to take into the Phase II trials in cancer, and evidence of a biologic effect of INB03,’ stated Tesi, who is also INmune Bio’s chief medical officer. ‘All of these goals have been met. Using data from this trial, we have begun planning a Phase II trial using INB03 as part of combination immunotherapy in patients with cancer.’ . . . The Phase I trial is an open-label, dose-escalation trial in patients with advanced solid tumors. Patients received INB03, a novel, second-generation soluble TNF (tumor necrosis factor) inhibitor that works by leveraging a dominant-negative technology. Positive preliminary data from the first two cohorts were released. That data will be followed by a final report later this year as the company advances the program into a Phase II study.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)INmune Bio Inc. (INMB) Stock Research Links
Scroll down for more posts ▼